Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Pembrolizumab (Keytruda) for Metastatic Urothelial Carcinoma (first line)
(Open for Input on Submission until March 6, 2019)

Cabozantinib (Cabometyx) for Renal Cell Carcinoma Resubmission
(Final Recommendation Issued as of February 20, 2019)

Bevacizumab (Brand Name: TBD) for Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer Biosimilar
(Pending Submission as of February 14, 2019)

Pembrolizumab (Keytruda) for squamous Non-Small Cell Lung Cancer
(Open for Input on Submission until February 25, 2019)

Lenvatinib (Lenvima) for Hepatocellular Carcinoma
(Open for Input on Submission until February 25, 2019)

Pomalidomide (Pomalyst) in combo with Dexamethasone and Bortezomib for Multiple Myeloma (second-line or beyond)
(Pending Submission as of February 6, 2019)

Atezolizumab (Tecentriq) for Small Cell Lung Cancer
(Pending Submission as of February 1, 2019)

Larotrectinib (Brand Name: TBD) for Neurotrophic Tyrosine Receptor Kinase Locally Advanced or Metastatic Solid Tumours
(Pending Submission as of January 24, 2019)

Abiraterone (Zytiga) for Prostate Cancer
(Pending Submission as of November 27, 2018)

Find a Drug Review